1. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry. (February 2020) Authors: Smit, H.J.M.; Aerts, J.; van den Heuvel, M.; Hiltermann, T.J.N.; Bahce, I.; Smit, E.F.; Dingemans, A-M.C.; Hendriks, L.E.; Stigt, J.A.; Schramel, F.M.N.H.; van Tinteren, H.; Groen, H.J.M. Journal: Lung cancer Issue: Volume 140(2020) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. (December 2018) Authors: Remon, J.; Hendriks, L.E.; Cabrera, C.; Reguart, N.; Besse, B. Journal: Cancer treatment reviews Issue: Volume 71(2018) Page Start: 47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. Issue 17 (November 2015) Authors: Hendriks, L.E.; Derks, J.L.; Postmus, P.E.; Damhuis, R.A.; Houben, R.M.A.; Troost, E.G.C.; Hochstenbag, M.M.; Smit, E.F.; Dingemans, A.-M.C. Journal: European journal of cancer Issue: Volume 51:Issue 17(2015:Nov.) Page Start: 2534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗